Orient Europharma Co Ltd
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk under the Karihome brand name; and healthcare supplement… Read more
Orient Europharma Co Ltd (4120) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.020x
Based on the latest financial reports, Orient Europharma Co Ltd (4120) has a cash flow conversion efficiency ratio of -0.020x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-157.84 Million) by net assets (NT$7.89 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Orient Europharma Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Orient Europharma Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Orient Europharma Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Orient Europharma Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ambra SA
WAR:AMB
|
0.005x |
|
GAIAM-A
F:GA6
|
0.003x |
|
Medeze Group PCL
BK:MEDEZE
|
N/A |
|
Kang Yong Electric Public Company Limited
BK:KYE
|
0.013x |
|
MegaStudy Co. Ltd
KQ:072870
|
0.031x |
|
Ardea Resources Ltd
AU:ARL
|
-0.022x |
|
Jong Shyn Shipbuilding Co. Ltd.
TWO:2644
|
N/A |
|
CKM Building Material
TWO:8930
|
0.054x |
Annual Cash Flow Conversion Efficiency for Orient Europharma Co Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Orient Europharma Co Ltd from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$5.82 Billion | NT$-121.11 Million | -0.021x | -233.83% |
| 2023-12-31 | NT$4.16 Billion | NT$64.67 Million | 0.016x | +124.46% |
| 2022-12-31 | NT$3.44 Billion | NT$-218.75 Million | -0.064x | -382.48% |
| 2021-12-31 | NT$3.45 Billion | NT$77.65 Million | 0.022x | -85.57% |
| 2020-12-31 | NT$3.91 Billion | NT$608.55 Million | 0.156x | +161.25% |
| 2019-12-31 | NT$3.81 Billion | NT$227.37 Million | 0.060x | +6.82% |
| 2018-12-31 | NT$4.14 Billion | NT$231.31 Million | 0.056x | -61.93% |
| 2017-12-31 | NT$4.10 Billion | NT$601.08 Million | 0.147x | +416.37% |
| 2016-12-31 | NT$3.92 Billion | NT$111.24 Million | 0.028x | -85.07% |
| 2015-12-31 | NT$3.38 Billion | NT$643.97 Million | 0.190x | -- |